华东医药(000963) - 2017 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2017 was CNY 7,149,353,940.70, representing a 15.95% increase compared to CNY 6,165,697,645.94 in the same period last year[8] - Net profit attributable to shareholders was CNY 544,014,117.67, up 25.11% from CNY 434,837,683.12 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 533,772,576.37, reflecting a 25.55% increase compared to CNY 425,161,251.90 in the previous year[8] - The basic earnings per share increased by 20.64% to CNY 1.1192 from CNY 0.9277 in the same quarter last year[8] - The company reported a net profit increase, with undistributed profits rising to CNY 3,542,902,649.71 from CNY 2,998,888,532.03, an increase of 18.19%[32] - The total profit for Q1 2017 was CNY 1,139,983,762.72, compared to CNY 103,166,718.97 in the prior year, indicating strong performance[42] - The company reported a total comprehensive income of CNY 1,113,087,822.04 for Q1 2017, a significant increase from CNY 84,288,272.44 in the previous year[43] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,240,506,789.18, a 5.42% increase from CNY 14,456,428,696.84 at the end of the previous year[8] - The total liabilities increased to CNY 7,059,665,642.87 from CNY 6,814,587,733.72, marking a rise of 3.61%[31] - The equity attributable to shareholders of the parent company reached CNY 7,822,538,036.92, up from CNY 7,278,523,919.24, indicating an increase of 7.48%[32] - The total current liabilities amounted to CNY 6,033,998,940.52, up from CNY 5,781,967,256.02, reflecting an increase of 4.36%[31] Cash Flow - The net cash flow from operating activities was negative at CNY -881,508,811.65, worsening by 42.29% compared to CNY -619,505,186.12 in the same period last year[8] - Operating cash inflow for Q1 2017 was CNY 6,340,401,022.18, up from CNY 5,557,448,398.01 in the previous year[45] - The total cash outflow from operating activities was 4,754,707,494.99 CNY, compared to 4,194,243,039.84 CNY in the previous period, indicating increased operational expenses[48] - The company experienced a net decrease in cash and cash equivalents of -681,362,538.96 CNY, compared to an increase of 135,956,487.46 CNY in the previous period[51] Shareholder Information - The company reported a total of 13,530 common shareholders at the end of the reporting period[12] - The largest shareholder, China Yuanda Group Co., Ltd., held 41.77% of the shares, amounting to 203,038,377 shares[12] Receivables and Inventory - Accounts receivable increased by 33.22% to ¥5,949,600,142.09, attributed to the expansion of sales[17] - Other receivables surged by 227.60% to ¥97,684,422.21, mainly due to an increase in advance payments[17] - Inventory decreased to CNY 1,546,041,617.65 from CNY 1,767,027,789.30, a decrease of 12.50%[33] Financial Expenses and Income - Financial expenses decreased by 56.35% to ¥11,215,326.72, resulting from reduced interest-bearing liabilities[17] - Investment income rose by 214.80% to ¥2,878,829.08, driven by increased net profits from joint ventures[17] - The company reported a significant increase in investment income, amounting to CNY 1,033,937,529.08, compared to CNY 30,479,782.14 in the previous period[42] Taxation - Tax refunds received increased by 58.06% to ¥1,077,563.01, reflecting higher tax rebate income[17] - The tax expenses for Q1 2017 were CNY 26,895,940.68, compared to CNY 18,878,446.53 in the previous year, indicating an increase in taxable income[42]